APA (7th ed.) Citation

S, S., G, P., C, B., I, M., S, P., E, B., . . . A, F. (2025). Correction: Sennato et al. Optimization of Lipoplexes Functionalized with a Sialic Acid Mimetic (F9-PEG) to Target the C1858T PTPN22 Variant for Preclinical Assessment of a Novel Immunotherapy in Endocrine Autoimmunity. Pharmaceutics 2025, 17, 710. Pharmaceutics, 17(12), . https://doi.org/10.3390/pharmaceutics17121601

Chicago Style (17th ed.) Citation

S, Sennato, et al. "Correction: Sennato Et Al. Optimization of Lipoplexes Functionalized with a Sialic Acid Mimetic (F9-PEG) to Target the C1858T PTPN22 Variant for Preclinical Assessment of a Novel Immunotherapy in Endocrine Autoimmunity. Pharmaceutics 2025, 17, 710." Pharmaceutics 17, no. 12 (2025). https://doi.org/10.3390/pharmaceutics17121601.

MLA (9th ed.) Citation

S, Sennato, et al. "Correction: Sennato Et Al. Optimization of Lipoplexes Functionalized with a Sialic Acid Mimetic (F9-PEG) to Target the C1858T PTPN22 Variant for Preclinical Assessment of a Novel Immunotherapy in Endocrine Autoimmunity. Pharmaceutics 2025, 17, 710." Pharmaceutics, vol. 17, no. 12, 2025, https://doi.org/10.3390/pharmaceutics17121601.